For DFS, EPHX2 was more likely to be a favorable factor in KIRC, PAAD, PRAD, and UVM, but deleterious in lymphoid neoplasm diffuse large B‐cell lymphoma (DLBC) and LGG (Figure 4C). Here, EPHX2 is linked to lymphoid neoplasm.